bms-986094
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2010 (NCT01159808)
Timeline
Indications
Mechanism of action
- RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)Oc2cccc3ccccc23)[C@@H](O)[C@@]1(C)O- Mol. weight
- 658.65 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL1209734 ↗
Also known as
- bms-986094
- bms-986094
- bms-986094
- bms-986094
- inx08189
- inx 08189
- inx-08189
- inx-08189
- inx-08189
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01629732 | Phase 2 | Mar 1, 2013 | Bristol-Myers Squibb |
| NCT01425970 | Phase 2 | May 1, 2012 | Bristol-Myers Squibb |
| NCT01471704 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2011 | Bristol-Myers Squibb |
| NCT01471717 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2011 | Bristol-Myers Squibb |
| NCT01445795 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2011 | Bristol-Myers Squibb |
| NCT01250366 | Phase 1 | Oct 1, 2010 | Bristol-Myers Squibb |
| NCT01159808 | Phase 1 | May 1, 2010 | Bristol-Myers Squibb |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 7 | 7 | 2 | 2010 |
1 organizations
Page 1 / 1